Close menu

January 4th, 2023 | 07:17 CET

Takeover fever 2023? BioNTech, Barrick Gold, Standard Lithium, Manuka Resources

  • Mining
  • Vanadium
  • Lithium
  • Biotechnology
  • Gold
Photo credits:

The pharmaceutical sector was already in takeover fever last year. BioNTech partner Pfizer, among others, made several acquisitions. The hunger for acquisitions is likely to continue in the current year as major pharmaceutical and biotech companies are looking to fill up their pipelines. The current year could also be exciting for gold stocks. In 2022, companies failed to keep pace with the positive gold price. Producers of raw materials for the energy transition could also get into takeover fever. Manuka Resources could benefit from the latest two trends. The Canadians have just carried out a capital measure to advance their projects. Corporations could also target specialists like Standard Lithium. Rumours that Tesla is looking at lithium projects have been doing the rounds for a long time. And what about Barrick Gold and BioNTech?

time to read: 5 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , BARRICK GOLD CORP. | CA0679011084 , STANDARD LITHIUM LTD | CA8536061010 , Manuka Resources Limited | AU0000090292

Table of contents:

    Manuka Resources: Facing revaluation due to vanadium project?

    There is a good chance that the Manuka Resources share will trend more friendly this year. The mining and exploration company completed its capital increase, which weighed on the share price at the end of 2022. Its project portfolio has three interesting raw materials: gold, silver, and the critical mineral vanadium. In order to advance these projects, the Australians received AUD 4.1 million in December. The new shares were placed at AUD 0.105. The stock is currently trading at AUD 0.085. "Recently, we have significantly advanced the resumption of silver production at Wonawinta, advanced a resource development plan at Mt Boppy and completed the acquisition of TTR - a project with the potential to be at the forefront of the green economy," said CEO Dennis Karp.

    Manuka's projects in detail: The Mt Bobby gold project was acquired in 2020. It is one of the historically richest gold mines in Australia. At the time, 500,000 ounces of gold were mined at an average grade of half an ounce per ton of ore. Manuka originally planned to mine 24,000 ounces of gold. But in fact, it is twice that amount. And the resource could be more productive than thought. A plan for further development is currently being drawn up.

    At the Wonawinta Silver project, the resource estimate is already available. It includes 51 million ounces, and once production begins, Manuka will become one of Australia's largest silver producers. A processing plant is already in operation and will initially be fed with historical stockpiles with a volume of 515,000 tons.

    Manuka's third project is also exciting. It is the South Taranaki Bight (STB) project, acquired in the fourth quarter of 2022. It is located offshore New Zealand and contains iron sands with vanadium, titanium and magnetite. Vanadium is a critical mineral and helps improve energy storage and battery durability. The mining license has already been granted. With a JORC resource of 3.8 bcm and a vanadium grade of 0.5%/t, Manuka could become the third largest vanadium producer in the world with a 15% market share. Revenue estimates are around pounds 55 million per annum. Manuka Resources' market capitalization is less than AUD 45 million. Yet the Australians have already generated revenues of AUD 53.5 million and positive operating cash flow of AUD 8.9 million in the past fiscal year (ended June 30).

    Barrick Gold: Focusing on own projects

    Officially, Barrick Gold is not currently looking around for takeover candidates. Instead, the Company is focusing on the development of its own projects. The focus is currently on the Reko Diq project in Pakistan. Production in one of the world's largest undeveloped copper-gold projects is expected to start in 2028. But there is still a long way to go, and Pakistan is anything but an easy place. Therefore, one cannot rule out that Barrick will jump on the takeover merry-go-round after all. The gold giant could afford it in any case. Debt has been reduced significantly in recent years, and operations are running smoothly. In the third quarter of 2022, expectations were exceeded, and production targets for the full year were confirmed. In contrast, experts expect Agnico Eagle to continue its M&A strategy. The Canadians aim to further reduce the gap to the industry giants Barrick and Newmont. The acquisitions of Detour Gold and Kirkland Lake Gold show that Agnico Eagle can also handle several larger transactions.

    Standard Lithium: Does price decline attract buyers?

    Standard Lithium's share price more than tripled in 2022. The disappointing share price performance could lure one or the other group. Lithium will likely be a commodity in great demand in the coming years. And Standard Lithium, after all, has two exciting projects. On the way to commercialization, the Company relies on cooperation with the German Lanxess Group. President of Standard Lithium, Dr Andy Robinson, says, "Our team has successfully negotiated and agreed upon a key agreement with Lanxess, the owner of the site, to exclusively secure the required land for our commercial facilities and allow us to begin work on-site at the proposed location of the first commercial lithium project. The data collected over the next few months will be critical for the OPD team to design the facility and place key equipment on the large land area available to Standard Lithium at Lanxess' South Plant. Once the key ground conditions are determined and the location of the major equipment can be established, engineering work can begin to link the Standard Lithium facility and Lanxess' existing brine infrastructure on the site. We look forward to announcing further developments as planning unfolds for the Company's first commercial lithium project." In addition to Lanxess, the second collaboration partner Koch Industries could swallow the lithium explorer. There is also ongoing speculation about Tesla taking at least a stake in a lithium company, extending its value creation.

    BioNTech: 163 million vaccine doses delivered to the federal government alone

    BioNTech's stock benefited yesterday from the news that Germany has committed to purchase about 375 million doses of the Corona vaccine. That is according to a response from the German government to a question from the AfD parliamentary group. There was no information about the price per dose. According to the Federal Ministry of Health, a total of about 163 million vaccine doses have been supplied by BioNTech/Pfizer to date. Another 60 million doses came from other manufacturers. Of the total nearly 223 million doses delivered, more than 85% have been vaccinated. Currently, about 7,000 vaccinations per day are being carried out. According to the German government, negotiations are underway via the EU Commission to cancel or reduce the additional orders for 2023 and 2024. Whether this will happen is likely dependent on the Corona pandemic's development in China. Due to the development in the Middle Kingdom, representatives of the EU countries want to meet today to discuss possible reactions. Regardless of how COVID-19 will proceed, BioNTech can go full throttle with its development due to the billions in profits. The focus now is on cancer research. The Mainz-based company's pipeline includes 19 product candidates in 24 ongoing clinical trials. Accordingly, there should be a positive news flow in the current year. In terms of acquisitions, BioNTech has so far focused on production capacities. It is unlikely that a research-based biotech company will be bought, but at least the financing should not fail. On the other hand, a takeover of BioNTech is also unlikely due to the shareholder base. In particular, the founders have repeatedly emphasized that they want to develop BioNTech independently.

    Barrick is one of the fundamental investments in the gold sector. The fact that it currently prefers to develop its own projects instead of making acquisitions carries risks and is not welcomed by every expert. Manuka Resources has developed positively operationally in the past year. If this continues in 2023, the share should also benefit. In the case of Standard Lithium, it is advisable to wait for a countermovement. The chart is heavily battered. At BioNTech, the new study results will determine the share price development.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET

    Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech

    • Biotechnology
    • Pharma

    The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.


    Commented by André Will-Laudien on December 7th, 2023 | 08:50 CET

    Snow chaos and climate madness, who is playing in the Premier League of the energy transition? Nel ASA, Power Nickel and Plug Power under the microscope

    • Mining
    • Nickel
    • BatteryMetals
    • renewableenergies
    • Energy

    Snow chaos and new record highs. While the DAX 40 demonstrates itself as the world's best blue-chip index, the German economy is currently navigating downward. It is not the earnings outlook that is presently driving share prices but the hope of lower interest rates. Meanwhile, the endless climate debates in Dubai continue. Among realists, however, there must be fears that the local oil lobby will not let a German know-it-all put a stop to the lavish margins with fossil fuels. There will, at least, be a friendly Arab nod to the 2050 climate goals and exclusive indulgence for the high-ranking German delegation. Whether this justifies federal expenditure of more than EUR 50 million is something we will leave uncommented. More important is a look at the top titles of the upcoming energy transition - where is the next 100 percenter lurking?


    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.